MRO Magazine

CORRECTING and REPLACING Growing Popularity of MI Spinal and Robot-assisted Surgeries Predicted to Drive the Global Spine Biologics Market Until 2020, Says Technavio


June 28, 2016
By Business Wire News

LONDON

Please replace the release dated June 17, 2016 with the following corrected version due to multiple revisions to the paragraph under “Global spine biologics market by allograft.”

The corrected release reads:

GROWING POPULARITY OF MI SPINAL AND ROBOT-ASSISTED SURGERIES PREDICTED TO DRIVE THE GLOBAL SPINE BIOLOGICS MARKET UNTIL 2020, SAYS TECHNAVIO

According to the latest research study released by Technavio, the global spine biologics market is expected to reach USD 1.74 billion in revenue by 2020.

This research report titled ‘Global Spine Biologics Market 2016-2020’, provides an in-depth analysis of market growth in terms of revenue and emerging market trends. This market research report also includes up to date analysis and forecasts for various product segments, including allograft, stem cells, BMP, DBM, and synthetic bone grafts.

Request sample report: http://bit.ly/1OfQEge

“The shift in preference to MI surgeries from open surgical method has led to the high adoption of spine biologics in MI spine surgeries. Traditional open surgeries can cause various post-operation complications such as pain, partially collapsed lungs, blood clots, fatigue, muscle atrophy, and infections. Many medical facilities are therefore conducting spinal fusion surgeries to repair the vertebrae and treat other spine diseases,” said Barath Palada, one of Technavio’s lead analysts for life sciences research.

Overview of emerging product categories:

  • Allograft
  • Stem cells
  • BMP

Global spine biologics market by allograft

The global spine biologics market by allografts generated USD 163.7 million in 2015. The market is expected to grow at a moderate rate during the forecast period. Rise in the number of spinal surgeries and an increase in spine disorders worldwide are key factors that will drive the market. Allograft tissue banks play a major role in market growth as they provide tissues to manufacturers for the production of allografts. Both Zimmer Biomet and NuVasive have partnerships with AlloSource, a non-profit organization that offers more than 200 types of precise bone skin, soft tissue, and customized allografts. AlloSource and Zimmer Biomet, through its predecessor organizations, entered into a partnership in 2002. AlloSource manufactures and private labels Puros DBM Block and Strip products for Zimmer Biomet. AlloSource entered into a partnership with NuVasive in 2009 to process its Osteocel Plus product for spine injuries. As per the agreement, AlloSource licensed NuVasive’s certain intellectual properties related to bone growth products containing MSCs.

Global spine biologics market by stem cells

The global spine biologics market by stem cells generated USD 161.1 million in 2015. Stem cells are used in different procedures of bone repair and regeneration. These procedures have no risk of rejection or disease transmission, thereby increasing their implementation for treating various bone conditions. Stem cell procedures are also used in treating sports-related injuries, chronic pain, and arthritis. Advances in genetic engineering have allowed modification of stem cells to induce the genetic expression of growth factors that enhance tissue reconstruction.

Several challenges in spine surgery have been addressed by experimenting with stem cell therapy. For instance, certain challenges in degenerative spinal disorders have been addressed through biological reconstruction of the disc by using a variety of growth factors and stem cells. In spine fusion, MSCs and adipose-derived stem cells (ADSCs) that are harvested from the bone marrow, adipose tissue, periosteum, or skeletal muscle have been demonstrated to have a significant effect on spinal fusion.

Global spine biologics market by BMP

The global BMP market is growing at a steady rate and accounted for a 20.51% share of the global spine biologics market in 2015. Two proteins BMP-2 and BMP-7 have been known to facilitate bone healing and are extensively used in bone fusion therapy. These proteins are used in recombinant DNA technology.

The bone graft is synthetically manufactured and commonly referred to as a recombinant human BMP (rhBMP). To date, nearly 20 BMPs are known to be available; however, only BMP 2, 4, 6, 7, and 9 have been proven to play a significant role in bone formation. Among these, BMP-2 is the most potent growth factor that induces MSC and osteoprogenitor cell differentiation into osteoblasts. rhBMP-2 is the only osteoinductive bone graft that has been approved by the FDA.

Browse related reports:

Do you need a report on a market in a specific geographical cluster or country but can’t find what you’re looking for? Don’t worry, Technavio also takes client requests. Please contact enquiry@technavio.com with your requirements and our analysts will be happy to create a customized report just for you.

About Technavio

Technaviois a leading global technology research and advisory company. The company develops over 2000 pieces of research every year, covering more than 500 technologies across 80 countries. Technavio has about 300 analysts globally who specialize in customized consulting and business research assignments across the latest leading edge technologies.

Technavio analysts employ primary as well as secondary research techniques to ascertain the size and vendor landscape in a range of markets. Analysts obtain information using a combination of bottom-up and top-down approaches, besides using in-house market modeling tools and proprietary databases. They corroborate this data with the data obtained from various market participants and stakeholders across the value chain, including vendors, service providers, distributors, re-sellers, and end-users.

If you are interested in more information, please contact our media team at media@technavio.com.

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 630 333 9501
UK: +44 208 123 1770
www.technavio.com
media@technavio.com